Intellia Therapeutics (NTLA)

Executive Summary

Intellia Therapeutics is a clinical-stage CRISPR/Cas9 genome editing company focused on developing in vivo and ex vivo therapies for genetic diseases. Its lead in vivo program, NTLA-2002, targets hereditary angioedema (HAE) and is currently in Phase 1/2 and Phase 3 trials, with promising early data showing durable reductions in plasma kallikrein levels and attack rates. Another key asset, NTLA-2001, has completed Phase 1 for transthyretin amyloidosis, demonstrating successful gene editing and protein knockdown. Intellia's platform has broad potential beyond liver targets, including ex vivo editing for oncology and autoimmune indications. The company faces competition from other gene-editing modalities but benefits from strong intellectual property and strategic partnerships. With a market cap of approximately $1.9B, Intellia is well-positioned in the gene editing space, though near-term risk remains tied to clinical data readouts and regulatory outcomes.

Upcoming Catalysts (preview)

• Q2 2026NTLA-2002 Phase 1/2 Topline Data in HAE80% success
• H2 2027NTLA-2002 Phase 3 Interim Analysis60% success
• H1 2026NTLA-2001 Regulatory Update or Next Trial Initiation50% success